<DOC>
	<DOCNO>NCT02461537</DOCNO>
	<brief_summary>This trial compare outcome two treatment strategy patient high-risk AML fail achieve maintain complete remission standard therapy . Patients randomize two strategy . The standard strategy aim achieve complete remission aggressive salvage chemotherapy use high dose cytarabine mitoxantrone , . The alternative less toxic disease-control strategy disease monitoring , necessary , low-dose cytarabine mitoxantrone prior allogeneic transplantation , perform soon possible .</brief_summary>
	<brief_title>Impact Remission Induction Chemotherapy Prior Allogeneic SCT Relapsed Poor-response Patients With AML ( ETAL3-ASAP )</brief_title>
	<detailed_description>Patients high-risk acute myeloid leukemia ( AML ) relapse show poor response induction chemotherapy dismal prognosis . For patient , allogeneic transplantation recommend treatment . While allogeneic transplantation may consider ultimate treatment concept , treatment path transplantation well define . The traditional approach pursue complete remission mean aggressive reinduction chemotherapy prior allogeneic transplantation . This approach associate potentially life-threatening toxicity limit efficacy . As result , patient reach allogeneic transplantation complete remission . To reduce number patient die ineligible transplantation due toxicity aggressive induction chemotherapy , bridge option explore . One promise alternative abstain remission induction . Instead , disease control mean less aggressive chemotherapy simply monitor leukemic proliferation consider . This randomized trial identify non-inferiority less toxic approach , compare standard approach remission induction aggressive chemotherapy prior allogeneic transplantation .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Male female patient 18 75 year age . Diagnosis AML accord WHO criterion . Patient fit aggressive induction chemotherapy transplantation assessment experience hematologist . HLAidentical sibling . HLAcompatible ( 8/8 ) unrelated donor complete confirmatory typing . One potential HLA compatible ( 8/8 ) donor plus least two backup donor , least 9/10 match &gt; 90 % probability . For relapse stratum : First AML relapse , define ≥5 % bone marrow blast / extramedullary AML manifestation . For poorresponders stratum : If patient ≤60 year old : High risk AML accord ELNcriteria ≥5 % bone marrow blast first cycle induction therapy . If patient &gt; 60 year old : Nonfavourable risk AML accord ELNcriteria ≥5 % bone marrow blast first cycle induction therapy . Acute promyelocytic leukemia ( APL ) . WBC count ≥50 GPt/L study inclusion . For patient poorresponder stratum first cycle induction therapy must contain HDAC , define cytarabine singledoses ≥1g/ m2 . Patient receive 80 % tolerable cumulative anthracycline dose ( see chapter 7.2. definition worksheet calculation ) . Severe organ dysfunction , . Uncontrolled infection time enrollment . History allogeneic transplantation . Manifestation AML central nervous system . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>